Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases

被引:35
|
作者
Wang, Jing [1 ,2 ]
Cao, Hong [1 ,2 ]
机构
[1] Chinese Acad Sci, Inst Hydrobiol, State Key Lab Freshwater Ecol & Biotechnol, Donghu South Rd 7, Wuhan 430072, Peoples R China
[2] Univ Chinese Acad Sci, Coll Adv Agr Sci, Beijing 100049, Peoples R China
基金
国家重点研发计划;
关键词
zebrafish; medaka; disease models; neurodegenerative; NEURONAL CELL-DEATH; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; ADULT ZEBRAFISH; MORPHOLOGICAL-CHANGES; EMBRYONIC LETHALITY; TAU PATHOLOGY; GENE HOMOLOG; OKADAIC ACID;
D O I
10.3390/ijms221910766
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Animal models of human neurodegenerative disease have been investigated for several decades. In recent years, zebrafish (Danio rerio) and medaka (Oryzias latipes) have become popular in pathogenic and therapeutic studies about human neurodegenerative diseases due to their small size, the optical clarity of embryos, their fast development, and their suitability to large-scale therapeutic screening. Following the emergence of a new generation of molecular biological technologies such as reverse and forward genetics, morpholino, transgenesis, and gene knockout, many human neurodegenerative disease models, such as Parkinson's, Huntington's, and Alzheimer's, were constructed in zebrafish and medaka. These studies proved that zebrafish and medaka genes are functionally conserved in relation to their human homologues, so they exhibit similar neurodegenerative phenotypes to human beings. Therefore, fish are a suitable model for the investigation of pathologic mechanisms of neurodegenerative diseases and for the large-scale screening of drugs for potential therapy. In this review, we summarize the studies in modelling human neurodegenerative diseases in zebrafish and medaka in recent years.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] The benefits and limitations of animal models for translational research in neurodegenerative diseases
    Jucker, Mathias
    NATURE MEDICINE, 2010, 16 (11) : 1210 - 1214
  • [22] Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview
    de Bem, Andreza Fabro
    Krolow, Rachel
    Farias, Hemelin Resende
    de Rezende, Victoria Linden
    Gelain, Daniel Pens
    Moreira, Jose Claudio Fonseca
    Duarte, Joao Miguel das Neves
    de Oliveira, Jade
    FRONTIERS IN NEUROSCIENCE, 2021, 14
  • [23] Genetically modified large animal models for investigating neurodegenerative diseases
    Yang, Weili
    Chen, Xiusheng
    Li, Shihua
    Li, Xiao-Jiang
    CELL AND BIOSCIENCE, 2021, 11 (01):
  • [24] Genetically modified large animal models for investigating neurodegenerative diseases
    Weili Yang
    Xiusheng Chen
    Shihua Li
    Xiao-Jiang Li
    Cell & Bioscience, 11
  • [25] Transgenic pig models for human neurodegenerative diseases
    Lai, Liangxue
    TRANSGENIC RESEARCH, 2014, 23 (01) : 191 - 192
  • [26] Canine models for human genetic neurodegenerative diseases
    Barsoum, SC
    Callahan, HM
    Robinson, K
    Chang, PL
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2000, 24 (05): : 811 - 823
  • [27] Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples
    Ugarte, Ana
    Corbacho, David
    Aymerich, Maria S.
    Garcia-Osta, Ana
    Cuadrado-Tejedor, Mar
    Oyarzabal, Julen
    NEUROTHERAPEUTICS, 2018, 15 (03) : 742 - 750
  • [28] Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples
    Ana Ugarte
    David Corbacho
    María S. Aymerich
    Ana García-Osta
    Mar Cuadrado-Tejedor
    Julen Oyarzabal
    Neurotherapeutics, 2018, 15 : 742 - 750
  • [29] Cellular and animal models to investigate pathogenesis of amyloid aggregation in neurodegenerative diseases
    Houfang Long
    Shuyi Zeng
    Dan Li
    Biophysics Reports, 2022, 8 (01) : 14 - 28
  • [30] Animal Models for Neurodegenerative Diseases Associated to Accumulation of Misfolded Protein Aggregates
    Soto, Claudio
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (08) : 1107 - 1107